ReviewCardiac failure review2023
Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View.
Review in Cardiac failure review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07270367 (Finerenone and Cardiac Remodeling), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Finerenone and Cardiac Remodeling: A Randomized, Double- Blind, Placebo-Controlled Study to Evaluate The Effects of Finerenone on Ventricular Remodeling
Who cites it
8 citing papers in PubMed.
- Noninvasive tracking of myocardial fibrosis in pressure-overload heart failure with [EJNMMI research · 2026Article
- Machine Learning Applications for Risk Stratification in Heart Failure with Preserved Ejection Fraction: A New Era in Cardiology.Diagnostics (Basel, Switzerland) · 2026Review
- Validation of shear wave elastography for assessing myocardial fibrosis in patients with end-stage heart failure.European heart journal. Cardiovascular Imaging · 2026Article
- Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review.Cureus · 2025Review
- Left Atrial Coupling Index Predicts Heart Failure in Patients with End Stage Renal Disease.Medicina (Kaunas, Lithuania) · 2024Article
- Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2024Review
- Challenges in Echocardiography for the Diagnosis and Prognosis of Non-Ischemic Hypertensive Heart Disease.Journal of clinical medicine · 2024Review
- Imaging and Heart Failure: What the Future Holds?Cardiac failure review · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is an important global health problem. Despite increased prevalence due to improved diagnostic options, limited improvement has been achieved in cardiac outcomes. HFpEF is an extremely complex syndrome and multimodality imaging is important for diagnosis, identifying its different phenotypes and determining prognosis. Evaluation of left ventricular filling pressures using echocardiographic diastolic function parameters is the first step of imaging in clinical practice. The role of echocardiography is becoming more popular and with the recent developments in deformation imaging, cardiac MRI is extremely important as it can provide tissue characterisation, identify fibrosis and optimal volume measurements of cardiac chambers. Nuclear imaging methods can also be used in the diagnosis of specific diseases, such as cardiac amyloidosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.